330 related articles for article (PubMed ID: 24729094)
1. Understanding HIV compartments and reservoirs.
Svicher V; Ceccherini-Silberstein F; Antinori A; Aquaro S; Perno CF
Curr HIV/AIDS Rep; 2014 Jun; 11(2):186-94. PubMed ID: 24729094
[TBL] [Abstract][Full Text] [Related]
2. Follicular Dendritic Cells of Lymph Nodes as Human Immunodeficiency Virus/Simian Immunodeficiency Virus Reservoirs and Insights on Cervical Lymph Node.
Dave RS; Jain P; Byrareddy SN
Front Immunol; 2018; 9():805. PubMed ID: 29725333
[TBL] [Abstract][Full Text] [Related]
3. Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.
Rose R; Nolan DJ; Maidji E; Stoddart CA; Singer EJ; Lamers SL; McGrath MS
AIDS Res Hum Retroviruses; 2018 Jan; 34(1):3-8. PubMed ID: 28691499
[TBL] [Abstract][Full Text] [Related]
4. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.
Chun TW; Fauci AS
AIDS; 2012 Jun; 26(10):1261-8. PubMed ID: 22472858
[TBL] [Abstract][Full Text] [Related]
5. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy.
Horiike M; Iwami S; Kodama M; Sato A; Watanabe Y; Yasui M; Ishida Y; Kobayashi T; Miura T; Igarashi T
Virology; 2012 Feb; 423(2):107-18. PubMed ID: 22196013
[TBL] [Abstract][Full Text] [Related]
6. Evolutionary mechanisms of retroviral persistence.
Whitney JB; Lim SY; Wainberg MA
AIDS Rev; 2011; 13(4):234-9. PubMed ID: 21975359
[TBL] [Abstract][Full Text] [Related]
7. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
8. Increased T cell trafficking as adjunct therapy for HIV-1.
Fryer HR; Wolinsky SM; McLean AR
PLoS Comput Biol; 2018 Mar; 14(3):e1006028. PubMed ID: 29499057
[TBL] [Abstract][Full Text] [Related]
9. Combating the HIV reservoirs.
van Marle G; Church DL; van der Meer F; Gill MJ
Biotechnol Genet Eng Rev; 2018 Apr; 34(1):76-89. PubMed ID: 29781356
[TBL] [Abstract][Full Text] [Related]
10. Immune activation, HIV persistence, and the cure.
Douek DC
Top Antivir Med; 2013; 21(4):128-32. PubMed ID: 24225078
[TBL] [Abstract][Full Text] [Related]
11. HIV reservoirs and the possibility of a cure for HIV infection.
Palmer S; Josefsson L; Coffin JM
J Intern Med; 2011 Dec; 270(6):550-60. PubMed ID: 21929712
[TBL] [Abstract][Full Text] [Related]
12. HIV reservoirs as obstacles and opportunities for an HIV cure.
Chun TW; Moir S; Fauci AS
Nat Immunol; 2015 Jun; 16(6):584-9. PubMed ID: 25990814
[TBL] [Abstract][Full Text] [Related]
13. Potential implication of residual viremia in patients on effective antiretroviral therapy.
Sahu GK
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):25-35. PubMed ID: 25428885
[TBL] [Abstract][Full Text] [Related]
14. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.
Bachmann N; von Siebenthal C; Vongrad V; Turk T; Neumann K; Beerenwinkel N; Bogojeska J; Fellay J; Roth V; Kok YL; Thorball CW; Borghesi A; Parbhoo S; Wieser M; Böni J; Perreau M; Klimkait T; Yerly S; Battegay M; Rauch A; Hoffmann M; Bernasconi E; Cavassini M; Kouyos RD; Günthard HF; Metzner KJ;
Nat Commun; 2019 Jul; 10(1):3193. PubMed ID: 31324762
[TBL] [Abstract][Full Text] [Related]
15. The Splice of Life: Does RNA Processing Have a Role in HIV-1 Persistence?
Pasternak AO; Berkhout B
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578332
[TBL] [Abstract][Full Text] [Related]
16. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.
Günthard HF; Havlir DV; Fiscus S; Zhang ZQ; Eron J; Mellors J; Gulick R; Frost SD; Brown AJ; Schleif W; Valentine F; Jonas L; Meibohm A; Ignacio CC; Isaacs R; Gamagami R; Emini E; Haase A; Richman DD; Wong JK
J Infect Dis; 2001 May; 183(9):1318-27. PubMed ID: 11294662
[TBL] [Abstract][Full Text] [Related]
17. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
[TBL] [Abstract][Full Text] [Related]
18. Curing HIV: Pharmacologic approaches to target HIV-1 latency.
Choudhary SK; Margolis DM
Annu Rev Pharmacol Toxicol; 2011; 51():397-418. PubMed ID: 21210747
[TBL] [Abstract][Full Text] [Related]
19. Persistent HIV-1 replication maintains the tissue reservoir during therapy.
Lorenzo-Redondo R; Fryer HR; Bedford T; Kim EY; Archer J; Pond SLK; Chung YS; Penugonda S; Chipman J; Fletcher CV; Schacker TW; Malim MH; Rambaut A; Haase AT; McLean AR; Wolinsky SM
Nature; 2016 Feb; 530(7588):51-56. PubMed ID: 26814962
[TBL] [Abstract][Full Text] [Related]
20. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
Darcis G; Berkhout B; Pasternak AO
Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
